Vycor Medical, Inc. (VMI) is dedicated to the creation, development, and commercialization of neurological medical devices and therapeutic solutions, operating in both the United States and European markets. The company's operations are divided into two primary business units. The Vycor Medical division specializes in neurosurgical instrumentation, providing devices such as the ViewSite Brain Access System—a critical retraction and access tool used in brain and spine surgeries. Conversely, the NovaVision segment delivers advanced, non-invasive, computer-based rehabilitation programs aimed at helping individuals with vision impairments resulting from strokes or other brain injuries. VMI has also established a strategic license and transition agreement with HelferApp GmbH, authorizing HelferApp to distribute NovaVision's products and therapies to patients and healthcare providers in Austria and Switzerland. The company's main clientele consists of hospitals and various medical professionals. Established in 2005, Vycor Medical, Inc. is headquartered in Boca Raton, Florida, and functions as a subsidiary of Fountainhead Capital Management Limited.
Subscribe to see VYCOR MEDICAL INC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
VYCOR MEDICAL INC is a medical devices company headquartered in Boca Raton, United States. It is publicly listed (VYCO) with a market capitalisation of $2.3M. Xcout tracks 7 named people at VYCOR MEDICAL INC, including Peter C. Zachariou (Chief Executive Officer & Director).
1 more named person on record for VYCOR MEDICAL INC, with roles, board committees and tenure — see the full roster →
A few of VYCOR MEDICAL INC's closest competitors — see the full list of competitors and alternatives →
NICO Corporation develops and provides minimally invasive neurosurgical technologies that integrate imaging and intervention for brain surgery. The company serves neurosurgeons and healthcare providers by offering patented tools and systems, such as the NICO Myriad and BrainPath, designed to improve clinical and economic outcomes.
NeuraMedica Inc. is a medical device company located in Oregon City, Oregon, dedicated to developing innovative products and surgical solutions for neurosurgery.
Elios Vision, Inc. provides next-generation glaucoma treatment solutions designed to address glaucoma during routine cataract surgery. The available evidence does not explicitly state its headquarters country.
Bioness Medical, Inc. is a medical technology provider headquartered in Valencia, California. Founded in 2004, the company specializes in innovative rehabilitation technologies, such as functional electrical stimulation, to help individuals with neurological conditions regain mobility and independence.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.